Open Orphan: World-leading expertise drives growth
Open Orphan (LON:ORPH) has rapidly restructured and integrated its Venn and hVIVO subsidiaries, and is delivering on its growth strategy by maximising its specialist capabilities and is converting a pipeline with an estimated value of over £100mln, to deliver long-term, profitable contracts.
This was highlighted by a recent win with a top-three global pharma company to deliver a respiratory syncytial virus (RSV) human challenge study clinical trial, reinforcing its world-leading position in the space. ORPH is also driving forward its strategy via expanding hVIVO lab services to third-parties and has signed a series of new contracts with antiviral, vaccine and respiratory therapeutic developers, including a COVID-19 vaccine testing contract with Codagenix.
Quick facts: Open Orphan PLC
Price: 19.7999 GBX
Market Cap: £131.84 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:
Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...FOR OUR FULL DISCLAIMER CLICK HERE